US Stock MarketDetailed Quotes

ANTX AN2 Therapeutics

Watchlist
  • 1.240
  • -0.010-0.80%
Close Apr 28 16:00 ET
  • 1.240
  • 0.0000.00%
Post 16:05 ET
37.32MMarket Cap-0.72P/E (TTM)

AN2 Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2024
(Q4)Dec 31, 2024
(Q3)Sep 30, 2024
(Q2)Jun 30, 2024
(Q1)Mar 31, 2024
(FY)Dec 31, 2023
(Q4)Dec 31, 2023
(Q3)Sep 30, 2023
(Q2)Jun 30, 2023
(Q1)Mar 31, 2023
Total revenue
0
0
0
0
0
0
0
0
0
0
Operating revenue
--0
--0
--0
--0
--0
--0
--0
--0
--0
--0
Cost of revenue
Gross profit
Operating expense
-21.66%54.55M
-54.25%8.61M
-35.25%11.77M
-4.34%15.88M
14.07%18.3M
64.77%69.64M
50.81%18.82M
54.46%18.18M
60.66%16.6M
108.76%16.04M
Selling and administrative expenses
-4.73%14.07M
-17.61%3.21M
-7.12%3.48M
21.81%3.73M
-10.19%3.64M
15.79%14.76M
4.62%3.9M
12.24%3.75M
-15.74%3.06M
97.76%4.05M
-General and administrative expense
-4.73%14.07M
-17.61%3.21M
-7.12%3.48M
21.81%3.73M
-10.19%3.64M
15.79%14.76M
4.62%3.9M
12.24%3.75M
-15.74%3.06M
97.76%4.05M
Research and development costs
-26.21%40.49M
-63.82%5.4M
-42.57%8.29M
-10.26%12.15M
22.28%14.66M
85.93%54.87M
70.46%14.92M
71.20%14.43M
102.12%13.54M
112.76%11.99M
Operating profit
21.66%-54.55M
54.25%-8.61M
35.25%-11.77M
4.34%-15.88M
-14.07%-18.3M
-64.77%-69.64M
-50.81%-18.82M
-54.46%-18.18M
-60.66%-16.6M
-108.76%-16.04M
Net non-operating interest income expense
12.49%5.47M
4.86M
Non-operating interest income
12.49%5.47M
----
----
----
----
--4.86M
----
----
----
----
Other net income (expense)
-5,295.35%-2.23M
-48.90%-4.38M
-166.26%-976K
81.30%1.45M
134.50%1.68M
-96.71%43K
-564.20%-2.94M
241.76%1.47M
274.18%797K
2,457.14%716K
Special income (charges)
---2.23M
--9K
---2.24M
----
----
--0
--0
--0
----
----
-Less：Restructuring and merger&acquisition
--2.23M
---9K
--2.24M
----
----
--0
--0
--0
----
----
Other non- operating income (expenses)
----
----
-13.99%1.27M
81.30%1.45M
134.50%1.68M
-96.71%43K
-564.20%-2.94M
241.76%1.47M
274.18%797K
2,457.14%716K
Income before tax
20.72%-51.32M
55.49%-7.52M
23.70%-12.75M
8.66%-14.44M
-8.44%-16.62M
-58.05%-64.73M
-42.70%-16.9M
-47.34%-16.71M
-56.17%-15.8M
-100.17%-15.32M
Income tax
Net income
20.72%-51.32M
55.49%-7.52M
23.70%-12.75M
8.66%-14.44M
-8.44%-16.62M
-58.05%-64.73M
-42.70%-16.9M
-47.34%-16.71M
-56.17%-15.8M
-100.17%-15.32M
Net income continuous Operations
20.72%-51.32M
55.49%-7.52M
23.70%-12.75M
8.66%-14.44M
-8.44%-16.62M
-58.05%-64.73M
-42.70%-16.9M
-47.34%-16.71M
-56.17%-15.8M
-100.17%-15.32M
Minority interest income
Net income attributable to the parent company
20.72%-51.32M
55.49%-7.52M
23.70%-12.75M
8.66%-14.44M
-8.44%-16.62M
-58.05%-64.73M
-42.70%-16.9M
-47.34%-16.71M
-56.17%-15.8M
-100.17%-15.32M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders
20.72%-51.32M
55.49%-7.52M
23.70%-12.75M
8.66%-14.44M
-8.44%-16.62M
-51.33%-64.73M
-42.70%-16.9M
-47.34%-16.71M
-56.17%-15.8M
-61.72%-15.32M
Basic earnings per share
37.23%-1.72
56.14%-0.25
33.85%-0.43
40.74%-0.48
29.11%-0.56
1.79%-2.74
6.56%-0.57
-10.17%-0.65
-55.30%-0.81
73.49%-0.79
Diluted earnings per share
37.23%-1.72
56.14%-0.25
33.85%-0.43
40.74%-0.48
29.11%-0.56
1.79%-2.74
6.56%-0.57
-10.17%-0.65
-55.30%-0.81
73.49%-0.79
Dividend per share
Currency Unit
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
--
--
(FY)Dec 31, 2024(Q4)Dec 31, 2024(Q3)Sep 30, 2024(Q2)Jun 30, 2024(Q1)Mar 31, 2024(FY)Dec 31, 2023(Q4)Dec 31, 2023(Q3)Sep 30, 2023(Q2)Jun 30, 2023(Q1)Mar 31, 2023
Total revenue 0000000000
Operating revenue --0--0--0--0--0--0--0--0--0--0
Cost of revenue
Gross profit
Operating expense -21.66%54.55M-54.25%8.61M-35.25%11.77M-4.34%15.88M14.07%18.3M64.77%69.64M50.81%18.82M54.46%18.18M60.66%16.6M108.76%16.04M
Selling and administrative expenses -4.73%14.07M-17.61%3.21M-7.12%3.48M21.81%3.73M-10.19%3.64M15.79%14.76M4.62%3.9M12.24%3.75M-15.74%3.06M97.76%4.05M
-General and administrative expense -4.73%14.07M-17.61%3.21M-7.12%3.48M21.81%3.73M-10.19%3.64M15.79%14.76M4.62%3.9M12.24%3.75M-15.74%3.06M97.76%4.05M
Research and development costs -26.21%40.49M-63.82%5.4M-42.57%8.29M-10.26%12.15M22.28%14.66M85.93%54.87M70.46%14.92M71.20%14.43M102.12%13.54M112.76%11.99M
Operating profit 21.66%-54.55M54.25%-8.61M35.25%-11.77M4.34%-15.88M-14.07%-18.3M-64.77%-69.64M-50.81%-18.82M-54.46%-18.18M-60.66%-16.6M-108.76%-16.04M
Net non-operating interest income expense 12.49%5.47M4.86M
Non-operating interest income 12.49%5.47M------------------4.86M----------------
Other net income (expense) -5,295.35%-2.23M-48.90%-4.38M-166.26%-976K81.30%1.45M134.50%1.68M-96.71%43K-564.20%-2.94M241.76%1.47M274.18%797K2,457.14%716K
Special income (charges) ---2.23M--9K---2.24M----------0--0--0--------
-Less：Restructuring and merger&acquisition --2.23M---9K--2.24M----------0--0--0--------
Other non- operating income (expenses) ---------13.99%1.27M81.30%1.45M134.50%1.68M-96.71%43K-564.20%-2.94M241.76%1.47M274.18%797K2,457.14%716K
Income before tax 20.72%-51.32M55.49%-7.52M23.70%-12.75M8.66%-14.44M-8.44%-16.62M-58.05%-64.73M-42.70%-16.9M-47.34%-16.71M-56.17%-15.8M-100.17%-15.32M
Income tax
Net income 20.72%-51.32M55.49%-7.52M23.70%-12.75M8.66%-14.44M-8.44%-16.62M-58.05%-64.73M-42.70%-16.9M-47.34%-16.71M-56.17%-15.8M-100.17%-15.32M
Net income continuous Operations 20.72%-51.32M55.49%-7.52M23.70%-12.75M8.66%-14.44M-8.44%-16.62M-58.05%-64.73M-42.70%-16.9M-47.34%-16.71M-56.17%-15.8M-100.17%-15.32M
Minority interest income
Net income attributable to the parent company 20.72%-51.32M55.49%-7.52M23.70%-12.75M8.66%-14.44M-8.44%-16.62M-58.05%-64.73M-42.70%-16.9M-47.34%-16.71M-56.17%-15.8M-100.17%-15.32M
Preferred stock dividends
Other preferred stock dividends
Net income attributable to common stockholders 20.72%-51.32M55.49%-7.52M23.70%-12.75M8.66%-14.44M-8.44%-16.62M-51.33%-64.73M-42.70%-16.9M-47.34%-16.71M-56.17%-15.8M-61.72%-15.32M
Basic earnings per share 37.23%-1.7256.14%-0.2533.85%-0.4340.74%-0.4829.11%-0.561.79%-2.746.56%-0.57-10.17%-0.65-55.30%-0.8173.49%-0.79
Diluted earnings per share 37.23%-1.7256.14%-0.2533.85%-0.4340.74%-0.4829.11%-0.561.79%-2.746.56%-0.57-10.17%-0.65-55.30%-0.8173.49%-0.79
Dividend per share
Currency Unit USDUSDUSDUSDUSDUSDUSDUSDUSDUSD
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions Unqualified Opinion--------Unqualified Opinion--------

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

No. Symbol Price
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
3.200
DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
DMZPY
8.690
New Fortress Energy
NFE
5.760
4
Hutchmed (China)
HCM
15.080
5
Lantheus
LNTH
102.700
Log In for the Full List
Unlock Now

Investment Course

Top 5 Industries for Stock Trading under Trump's Second Term
Stocks & Industries to Watch Under Trump's Second Presidency
With mooomoo, find out which stocks and industries may benefit from Trump's second presidency, based on his first administration's track record.

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More
MicroStrategy Q4 2024 earnings conference call

Reassessing Chinese Assets

Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.